Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Shares of Immuneering Corporation IMRX were up 5.1% yesterday after the company announced the dosing of the first patient in a pivotal phase III study evaluating its lead product candidate, atebimetinib (IMM-1-104), in combination with modified gemcitabine/nab-paclitaxel (mGnP) for the first-line treatment of metastatic pancreatic cancer.

The global phase III MAPKeeper 301 study will evaluate the safety and efficacy of atebimetinib, a dual MEK inhibitor plus mGnP, in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who have received no prior systemic anti-cancer therapy.

In the MAPKeeper 301 study, patients will be randomized to receive either atebimetinib (320 mg once daily) in combination with mGnP or standard-of-care GnP alone.

The primary endpoint of the study is overall survival (OS), while key secondary endpoints include progression-free survival, overall response rate, disease control rate, safety and tolerability and quality of life.

Top-line data from the MAPKeeper 301 study is expected to be announced in mid-2028.

IMRX Price Performance

Year to date, shares of Immuneering have declined 37.4% compared with the industry’s decrease of 3.3%.Zacks Investment Research

Image Source: Zacks Investment Research

IMRX's Updates on Atebimetinib Development

In January 2026, the company reported positive updated OS and safety data from the phase IIa study arm evaluating atebimetinib plus mGnP for treating first-line pancreatic cancer.

Data from the study showed that the combination of atebimetinib plus mGnP led to a 64% OS at 12 months compared to 35% for the standard of care in the given patient population.

The company is also developing atebimetinib as a monotherapy in third-line pancreatic cancer.

Beyond pancreatic cancer, Immuneering is evaluating atebimetinib in combination with Regeneron's REGN anti-PD-1 therapy, Libtayo (cemiplimab), in a phase II study in patients with first-line RAS-mutant non-small-cell lung cancer (NSCLC). Dosing in the study is expected to begin in the second half of 2026.

In February 2025, Immuneering entered into a collaboration with Regeneron to evaluate atebimetinib in combination with Libtayo for treating NSCLC.

Per this agreement, Immuneering will fund the planned studies while REGN will supply Libtayo, which is approved for multiple cancer indications.

Immuneering Corporation PriceImmuneering Corporation Price

Immuneering Corporation price | Immuneering Corporation Quote

IMRX's Zack Rank & Stocks to Consider

Immuneering currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Liquidia Corporation LQDA and Immunocore IMCR, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Story Continues

Over the past 60 days, estimates for Liquidia’s 2026 EPS have increased to $2.97 from $1.50. Over the same period, EPS estimates for 2027 have risen to $4.81 from $2.91. LQDA shares have surged 107.7% year to date.

Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.

Over the past 60 days, estimates for Immunocore’s 2026 bottom line have improved from a loss of 88 cents per share to earnings of 6 cents. Over the same period, EPS estimates for 2027 have risen from 24 cents to 87 cents. IMCR shares have lost 17.5% year to date.

Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 46.66%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report

Liquidia Corporation (LQDA) : Free Stock Analysis Report

Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report

Immuneering Corporation (IMRX) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Novo Nordisk NVO shares gained 2.7% on Thursday as investors focused on a major regulatory milestone for its obesity franchise, helping offset concerns stemming from NVO's disclosure of an IT security incident. The stock's advance reflected optimism around the U.K. Medicines and Healthcare products Regulatory Agency ("MHRA") approval of the Wegovy pill (oral semaglutide 25mg) for chronic weight management in adults with obesity or overweight and at least one weight-related condition. The therapy is indicated as an adjunct to a reduced-calorie diet and increased physical activity.

The approval makes the United Kingdom the first country in Europe to authorize a daily GLP-1 weight-loss pill, offering patients a convenient non-injectable alternative to weekly obesity treatments, with commercial availability via private prescription expected within weeks. In the United Kingdom, the drug is already approved as a once-weekly injection for reducing major cardiovascular events and easing HFpEF symptoms in obese patients.

Investors viewed the approval as strategically important, marking the third authorization for the Wegovy pill after the United States and the UAE. The oral therapy expands Novo Nordisk's obesity portfolio beyond injectable treatments, helping reach patients who are reluctant to use injections while offering the convenience of a daily pill and the potential for stronger treatment adherence. As the first approved daily GLP-1 weight-loss pill in Europe, the Wegovy pill strengthens Novo Nordisk's position in the fast-growing weight-management market, creating an additional avenue for future growth.

Year to date, NVO shares have lost 13.6% against the industry's 4.5% growth.Zacks Investment Research

Image Source: Zacks Investment Research

The positive regulatory news appeared to outweigh concerns about a cybersecurity incident disclosed by Novo Nordisk on the same day in a separate press release. The company reported unauthorized access to a limited number of internal IT systems and said certain non-public data, including personal information, had been copied externally without authorization. NVO has engaged external cybersecurity experts, notified relevant authorities and implemented containment measures, including temporarily taking some internal systems offline.

While the investigation remains ongoing and the incident could expose the company to regulatory scrutiny, remediation costs and reputational risks, Novo Nordisk stated that its core business operations have not been affected. The market's reaction suggests investors currently view the breach as a manageable operational issue, while assigning greater weight to the long-term commercial significance of Wegovy pill's landmark U.K. approval.

Story Continues

How Effective Is NVO's Wegovy Pill for Obesity?

The MHRA approval of Novo Nordisk's Wegovy pill was primarily based on robust late-stage clinical evidence from the phase III OASIS development program. The global program comprised four studies enrolling about 1,300 patients with obesity. A key 64-week phase IIIb study, OASIS 4, evaluated the efficacy and safety of the Wegovy pill compared to placebo in 307 adults with obesity or overweight with one or more comorbidities.

Results from OASIS 4 demonstrated strong and clinically meaningful weight loss, where obesity patients treated with the Wegovy pill achieved a mean reduction of 16.6% when treatment was adhered to. The magnitude of weight loss was comparable to that of injectable Wegovy 2.4 mg, with one in three patients achieving 20% or greater weight reduction. Importantly, the safety and tolerability profile of oral Wegovy was consistent with prior semaglutide studies, reinforcing confidence in its use. Novo Nordisk also noted that no currently available oral GLP-1 therapy matches the level of weight loss achieved with the Wegovy pill in clinical studies.

Per Novo Nordisk, obesity is a complex chronic disease affecting approximately 15 million people in the United Kingdom, with the prevalence of overweight and obesity among adults projected to reach 71% by 2040. The company emphasized that obesity requires long-term management and that treatment decisions, including the use of pharmacotherapy, should be tailored to individual patients through shared decision-making between healthcare providers and patients.

Novo Nordisk expects the approval and launch of the Wegovy pill in other select markets in the second half of 2026.

Novo Nordisk A/S Price and ConsensusNovo Nordisk A/S Price and Consensus

Novo Nordisk A/S price-consensus-chart | Novo Nordisk A/S Quote

NVO's Zacks Rank & Stocks to Consider

Novo Nordisk currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Liquidia Corporation LQDA, Indivior Pharmaceuticals INDV and Immunocore IMCR, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Liquidia Corporation's 2026 EPS have increased from $1.50 to $2.97. Over the same period, EPS estimates for 2027 have also increased from $2.91 to $4.81. LQDA shares have rallied 107.7% year to date.

Liquidia Corporation'searnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.

Over the past 60 days, estimates for Indivior Pharmaceuticals' 2026 earnings per share have increased from $3.33 to $4.05. Over the same period, EPS estimates for 2027 have risen to $4.27 from $3.66. INDV shares have gained 6.3% year to date.

Indivior Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.

The estimate for Immunocore's 2026 EPS is currently pegged at 6 cents. In the past 60 days, the estimates for its 2027 EPS have increased from 24 cents to 87 cents. IMCR shares have lost 17.5% year to date.

Immunocore's earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 46.66%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Novo Nordisk A/S (NVO) : Free Stock Analysis Report

Liquidia Corporation (LQDA) : Free Stock Analysis Report

Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report

Indivior Pharmaceuticals Inc. (INDV) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Bayer BAYRY announced that the European Medicines Agency (EMA) has validated the marketing authorization application for its investigational, once-daily, oral Factor XIa inhibitor, asundexian, for the prevention of ischemic stroke in adults after a non-cardioembolic ischemic stroke or a high-risk transient ischemic attack (TIA). This marks the completion of the regulatory application submission process and the beginning of the EMA’s centralized review procedure.

Bayer noted that stroke is an increasing public health challenge, affecting approximately 10 million people in Europe living with its long-term consequences, while more than one million new cases are reported each year. BAYRY added that stroke remains the world's and Europe's second-leading cause of death, placing a substantial burden on healthcare systems, with global costs estimated at $891 billion annually.

Shares of Bayer have lost 6.1% year to date against the industry’s 4.8% growth.Zacks Investment Research

Image Source: Zacks Investment Research

BAYRY’s EU Filing for Asundexian Supported by Phase III Data

Bayer’s marketing application for asundexian to the EMA is supported by encouraging data from the phase III OCEANIC-STROKE study. The study investigated the efficacy and safety of asundexian 50 mg compared to placebo for the prevention of ischemic stroke in patients after a non-cardioembolic ischemic stroke or high-risk TIA in combination with antiplatelet therapy. It enrolled 12,327 patients worldwide.

The primary efficacy endpoint was time to ischemic stroke, and the primary safety endpoint was major bleeding.

Bayer reported that in the OCEANIC-STROKE study, asundexian significantly reduced ischemic stroke by 26% in patients after a non-cardioembolic ischemic stroke or high-risk TIA, compared to placebo, both in combination with antiplatelet therapy, with no increase in the risk of International Society on Thrombosis and Hemostasis major bleeding.

The benefit was consistent across all major patient subgroups, regardless of age, sex, stroke subtype, stroke severity, or background antiplatelet regimen. Asundexian is viewed as a potential blockbuster opportunity in a market where the risk of recurrent stroke remains high.

Bayer is also pursuing broader global regulatory approvals for asundexian. Last month, the FDA accepted BAYRY’s regulatory filing for asundexian to prevent ischemic stroke in patients following a non-cardioembolic ischemic stroke or TIA under its Priority Review pathway, potentially accelerating the regulatory review process in the United States. A filing for the candidate for the same indication is also currently under review in Japan.

Story Continues

In addition to the U.S. and Japan filings, China’s regulatory body also recently accepted Bayer’s marketing authorization application for the therapy to treat the above indication and granted it Priority Review designation.

Bayer Aktiengesellschaft Price and ConsensusBayer Aktiengesellschaft Price and Consensus

Bayer Aktiengesellschaft price-consensus-chart | Bayer Aktiengesellschaft Quote

BAYRY’s Zacks Rank & Other Stocks to Consider

Bayer currently carries a Zacks Rank #2 (Buy).

Some other top-ranked stocks in the biotech sector are Liquidia Corporation LQDA, Indivior Pharmaceuticals INDV and Immunocore IMCR, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Liquidia Corporation’s 2026 EPS have increased from $1.50 to $2.97. Over the same period, EPS estimates for 2027 have also increased from $2.91 to $4.81. LQDA shares have rallied 89.2% year to date.

Liquidia Corporation’searnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.

Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have increased from $3.33 to $4.05. Over the same period, EPS estimates for 2027 have risen to $4.27 from $3.66. INDV shares have gained 6.1% year to date.

Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.

The estimate for Immunocore’s 2026 EPS is currently pegged at 6 cents. In the past 60 days, the estimates for its 2027 EPS have increased from 24 cents to 87 cents. IMCR shares have lost 19.6% year to date.

Immunocore’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 46.66%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report

Liquidia Corporation (LQDA) : Free Stock Analysis Report

Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report

Indivior Pharmaceuticals Inc. (INDV) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Sanofi SNY announced that it is discontinuing the phase III MOBILIZE study, which is evaluating its investigational drug, riliprubart, in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) refractory to standard-of-care (SoC) treatment.

This decision comes after an independent committee conducted an interim analysis of the data from the MOBILIZE study and concluded that riliprubart was “unlikely to provide sufficient efficacy” in this difficult-to-treat patient population. The analysis did not identify any new safety concerns associated with the drug.

With this setback, Sanofi stated that it will assess the future of other ongoing riliprubart studies, including the phase III VITALIZE study in CIDP patients receiving maintenance intravenous immunoglobulin (IVIg) therapy.

CIDP is a rare disorder affecting the peripheral nervous system, marked by progressive muscle weakness and sensory loss.

SNY’s Stock Performance

Following this announcement, Sanofi's shares were trading lower in pre-market trading today. While the company assured investors that the MOBILIZE study termination does not affect its financial outlook for 2026, the setback raises concerns about the future of riliprubart, which was previously viewed as one of its promising pipeline candidates.

Sanofi had previously outlined plans for a regulatory filing in 2027 based on data from the MOBILIZE and VITALIZE studies. The drug has also secured orphan drug designation in both the United States and Europe for CIDP. Although VITALIZE remains ongoing, the loss of one pivotal study raises uncertainty about riliprubart's regulatory and commercial prospects.

Year to date, the stock has lost nearly 8% against the industry’s 4% growth.Zacks Investment Research

Image Source: Zacks Investment Research

More on Sanofi’s Riliprubart

An investigational IgG4 humanized monoclonal antibody, riliprubart, is designed to selectively inhibit activated C1s in the classical complement pathway of the innate immune system.

Apart from CIDP, Sanofi is assessing riliprubart in a phase II study for antibody-mediated rejection (AMR) in kidney transplant recipients. The study is evaluating the drug in patients at risk of developing AMR as well as those with active AMR, reflecting the company's efforts to explore the therapy's potential across multiple immune-mediated diseases.

SNY’s Zacks Rank

Sanofi currently carries a Zacks Rank #3 (Hold).

Sanofi PriceSanofi Price

Sanofi price | Sanofi Quote

Key Picks Among Biotech Stocks

Some better-ranked stocks from the sector are Immunocore IMCR and Indivior Pharmaceuticals INDV, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Story Continues

Over the past 60 days, estimates for Immunocore’s 2026 bottom line have improved from a loss per share of 88 cents to earnings of 6 cents. Over the same period, estimates for 2027 EPS have risen from 24 cents to 87 cents. IMCR’s shares have lost 18% year to date.

Immunocore’s earnings beat estimates in three of the trailing four quarters but missed the mark on one occasion, delivering an average surprise of 46.66%.

Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 EPS have increased from $3.33 to $4.05. Over the same period, EPS estimates for 2027 have risen from $3.66 to $4.27. INDV’s shares are up nearly 7% year to date.

Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 65.44%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Sanofi (SNY) : Free Stock Analysis Report

Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report

Indivior Pharmaceuticals Inc. (INDV) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Johnson & Johnson hat angekündigt, dass es eine definitive Vereinbarung zur Übernahme des kalifornischen Biotechnologieunternehmens Firefly Bio für 1 Milliarde US-Dollar in bar geschlossen hat. Durch die Übernahme wird das Firelink-Abbauplatfom von Firefly Bio zu JNJ's Pipeline hinzugefügt.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Die Gilead Sciences, Inc. (GILD) hat positive Ergebnisse aus der spät-stufigen IDEAL-Studie in Patienten mit primärer bilärer Cholangitis (PBC) vorgestellt. Die Studie zeigte, dass Livdelzi (Seladelpar) die Proportionszahl der Patienten erhöht hat, die nach 52 Wochen eine Normalisierung der alkalischen Phosphatase (ALP) erreicht haben, im Vergleich zum Placebo.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Die Firma Amgen hat bekannt gegeben, dass die Europäische Kommission (EC) die Zulassung für das Medikament Imdylltra (tarlatamab) zur Behandlung von Erwachsenen mit ausgedehntem Stadium des kleinzelligen Lungenkrebses erteilt hat. Die Entscheidung der EC basiert auf den Ergebnissen der Phase-III-Studie DeLLphi-304, die zeigte, dass das Medikament das Risiko eines Todes um 40% reduziert und auch die mittlere Gesamtsurvivalfähigkeit um mehr als fünf Monate gegenüber der Standardbehandlung verlängerte. Das Medikament ist bereits in den USA für eine ähnliche Indikation zugelassen, wo es unter dem Markennamen Imdelltra verkauft wird.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Merck hat bekannt gegeben, dass die FDA der investigativen oralen spezifischen KRAS G12C-Hemmer calderasib (MK-1084) die Bezeichnung als Breakthrough-Therapie für das Behandeln bestimmter Patienten mit neu diagnostiziertem metastatischem KRAS G12C-mutanten nicht kleinen Zellkarzinom (NSCLC) erteilt hat.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Die Gilead Sciences Inc. (GILD) hat bekannt gegeben, dass die FDA das Medikament Hepcludex (Bulevirtid-Gmod) für Erwachsene mit chronischer Hepatitis-D-Virus-Infektion zugelassen hat. Der Zulassung vorausgegangen waren Daten aus der Phase-III-Studie MYR301, in der Hepcludex eine statistisch signifikante Verbesserung bei kombinierten virologischen und biochemischen Reaktionen nach 48 Wochen gegenüber einer verzögerten Behandlung aufwies. Das Medikament zeigte Reduzierungen von HDV-RNA-Werten und Normalisierung der Alanin-Aminotransferase, mit nachhaltiger Wirksamkeit und allgemein gunstigem Verträglichkeitsprofil bis zu 144 Wochen Behandlungsdauer. Die chronische HDV-Infektion gilt als die schwerwiegendste Form der viralen Hepatitis aufgrund ihrer schnellen Progression zur Leberinsuffizienz und -tod, was den erheblichen Bedarf an wirksamen Behandlungen unterstreicht. Es wird geschätzt, dass HDV in den USA etwa 40.000 bis 80.000 Menschen infiziert hat, die chronische Hepatitis-B-Virus-Infektion haben. Hepcludex (Bulevirtid-Gmod) 8,5 mg wurde für Erwachsene mit chronischer HDV-Infektion ohne Zirrhose oder mit kompensierter Zirrhose unter der FDA-Zulassung für beschleunigte Zulassung zugelassen. Die weitere Zulassung könnte von der Bestätigung des klinischen Nutzens in laufenden Studien abhängig sein. GILD hat auch bekannt gegeben, dass das Komitee für medizinische Produkte für den menschlichen Gebrauch (CHMP) der Europäischen Arzneimittelagentur eine positive Stellungnahme zur Zulassung von Trodelvy als Monotherapie für Erwachsene mit unresektierbaren lokal fortgeschrittenen oder metastasierten Triple-Negativ-Brustkrebs (TNBC), die keine vorherige systemische Behandlung für metastatische Krankheit erhalten haben und nicht für PD-1- oder PD-L1-Hemmer-Therapie in Frage kommen, empfohlen hat. Eine endgültige Entscheidung der Europäischen Kommission ist für das Jahr 2026 erwartet. Der TNBC ist eine aggressive Brustkrebs-Sonderform mit schlechten Überlebensaussichten und vielen Patienten erhalten nur eine Linie Behandlung im metastasierten Setting, was den Bedarf an wirksamen ersten-Linien-Behandlungen unterstreicht. Die CHMP-Empfehlung basierte auf Ergebnissen aus der Phase-III-Studie ASCENT-03, in der Trodelvy signifikant die Progressionsfreifrist gegenüber Standardchemotherapie verbesserte. Die Studie zeigte eine 38%ige Reduktion des Risikos von Krankheitsprogress oder Tod bei Patienten, die nicht für PD-1/PD-L1-Hemmer-Therapie in Frage kamen.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Bayer BAYRY hat angekündigt, dass die FDA dem Medikament Sevabertinib den Prioritätsstatus für die Behandlung von erwachsenen Patienten mit lokal fortgeschrittenem oder metastasierten nicht kleinen Zell-Lungenkrebs (NSCLC) gewährt hat. Diese Patienten haben HER2- (ERBB2)-Tyrosinkinasedomänenaktivierende Mutationen. Sevabertinib ist ein neues orales, reversibles Small-Molecule-Tyrosinkinaseninhibitor (TKI), der selektiv die mutierten HER2, einschließlich HER2-Exon 20-Einfügung und HER2-Punktmutationen, sowie Epidermalfaktor-Rezeptoren (EGFR) angreift. Es zeigt eine hohe Selektivität für mutierte EGFR gegenüber der Wildform an. Ein Prioritätsstatus bedeutet, dass die FDA das Ziel hat, innerhalb von sechs Monaten auf eine Anwendung zu reagieren, im Gegensatz zu zehn Monaten bei Standardprüfung. Die FDA gewährt Prioritätsstatus für Therapien, die, wenn sie genehmigt werden, erhebliche Verbesserungen in der Sicherheit oder Wirksamkeit bei der Behandlung, Diagnose oder Verhütung schwerer Bedingungen bieten.